<DOC>
	<DOCNO>NCT00476541</DOCNO>
	<brief_summary>The overall objective improve cure rate child newly diagnose acute myeloid leukemia ( AML ) undergo risk-adapted therapy . Stem cell transplantation ( SCT ) reserve high-risk patient define cytogenetics response chemotherapy . The efficacy toxicity Gemtuzumab ozogamicin ( GO , Mylotarg ) evaluate .</brief_summary>
	<brief_title>NOPHO-AML 2004 Study Children With Acute Myeloid Leukemia</brief_title>
	<detailed_description>The overall objective improve cure rate pediatric patient newly diagnose acute myeloid leukemia ( AML ) . The specific aim follow : 1.1 Therapeutic aim To improve event-free survival ( EFS ) AML patient undergo risk-adapted therapy . To improve overall survival ( OS ) reserve stem cell transplantation ( SCT ) high-risk patient base cytogenetics response induction therapy . To compare outcome SCT use HLA-matched sibling donor ( MSD ) HLA-matched unrelated donor ( MUD ) . To assess efficacy toxicity Gemtuzumab ozogamicin ( GO , Mylotarg ) post consolidation therapy . 1.2 Biologic aim To study minimal residual disease ( MRD ) level blood bone marrow ( BM ) define time point study prognostic impact MRD . To test vitro cellular drug resistance diagnosis relapse , correlate data background factor clinical outcome . To secure storage biological material diagnosis future biologic study</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Gemtuzumab</mesh_term>
	<criteria>AML define diagnostic criterion , Age &lt; 19 year time study entry , Written inform consent Previous chemo radiotherapy , AML secondary previous bone marrow failure syndrome , Down syndrome ( DS ) , Acute promyelocytic leukemia ( APL ) , Juvenile myelomonocytic leukemia ( JMML ) , Myelodysplastic syndrome ( MDS ) , Fanconi anemia , Positive pregnancy test</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>AML</keyword>
	<keyword>Children</keyword>
	<keyword>Gemtuzumab ozogamicin</keyword>
	<keyword>Stem cell transplantation</keyword>
</DOC>